Experimental results show new drug improves dry eye symptoms :: InvestMacro


This study data was reinforced by Aldeyra Therapeutics Inc. Therapeutic pathway for a new drug application, likely in Q3/22, a HC Wainwright & Co.

Aldeyra Therapeutics Inc.’s (ALDX: NASDAQ) Reproxalab has been shown, by results of recent clinical trials, to be effective in treating dry eye disease, according to HC Wainwright & Co., analyst Matthew Coffield. In a research note dated July 13. These data bode well for the New Drug Application (NDA) that the biotech intends to submit to the US Food and Drug Administration (FDA) for reproxalab, likely in the third quarter of the year 22.

Reproxalap is a RASP, or reactive aldehyde species, 0.25% ophthalmic solution to be administered topically.

“Reproxalap has shown a strong and consistent benefit for dry eye disease,” Coffield added. “We view RASP inhibition as representing a viable new pathway in addressing the current therapeutic limitations of dry eye disease.”

Coffield noted that approved dry eye disease treatments on the market can take months to have a noticeable effect, have inconsistent responses among patients, can be uncomfortable, and often cause patients to stop using them.



Caufield highlighted that the newly released positive data, from the vehicle-controlled crossover trial of reproxalap, show that the drug met both primary and secondary endpoints of statistical significance.

With riproxalab, study participants showed improvement in:

1) Dry eye redness in the eye chamber, primary end point, (p = 0.0004). Benefit is observed initially at 10 minutes and then within the last 90 minutes after entering the room.

2) Schirmer’s test to assess tear production 1 day after dosing, primary end point, (p = 0.0005). This result supports the previous dosing activity and the activity of the fourth dose versus the one-day dosing.

3) Schirmer’s test greater than or equal to 10 mM responder analysis, secondary endpoint, (p = 0.0361).

Other secondary endpoints of reproxalap showed benefit in dry eyes (p = 0.0068), discomfort (p < 0.0001), severity (p = 0.0001), tongue (p = 0.0001), burning (p < 0.0001) and itching (p = 0.0003). ).

Coffield wrote that these “reflect a broad representation of potential symptom benefit within a characteristically heterogeneous set of indicators”.

Reproxalap has also shown a positive safety and tolerability profile. The most common adverse drug-related event was mild and transient discomfort at the site of administration.

“This more recent data set provides direct support for RASP inhibition of previous TRANQUILITY-2 and TRANQUILITY experiments,” Coffield commented.

In the next step for its reproxalap program, Aldeyra will meet with the FDA for feedback before introducing an NDA, the most likely near-term trigger for the drug’s developer, according to Caufield.

The analyst also noted that the FDA does not require that all potential dry eye disease drug benefits be shown in a single clinical trial. Instead, each benefit must be proven in more than one clinical trial. This is the case with reproxalap, which simplifies the path of approval for it.

HC Wainwright has a buy rating and a stock price target of $15 on Aldeyra, with a current share price of approximately $5.06.

Disclosures

1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. They or their family members own the securities of the following companies mentioned in the article: None. Their salaries or their family members are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are sponsors of Streetwise Reports billboards: None. click over here For important disclosures about sponsor fees.

3) Comments and opinions expressed are those of specific experts and are not those of Streetwise Reports or its officials. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The material does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action the reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ full legal terms of use disclaimer. This article is not a solicitation to invest. Streetwise Reports does not provide general or specific investment advice and the information in Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the businesses, products, services, or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the Site, may have a long or short position in said securities. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or selling such securities on the open market or otherwise from the time of the decision to publish an article until three business days after the article is published. The foregoing prohibition does not apply to articles that merely repeat in substance the company’s previously published versions.

6) This article does not constitute medical advice. The officers, employees, and contributors of Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

HCWainwright & Co. Disclosures , Aldeyra Therapeutics, July 13, 2022

HC Wainwright & Co, LLC (the “Company”) is a member of FINRA, SIPC, and a US registered broker-dealer.

I, Matthew Caufield and Andrew S. Phin, certify that 1) all opinions expressed in this report accurately reflect my personal opinions about any and all securities or issuers being discussed; and 2) no part of my salary was or would be directly or indirectly related to the specific recommendation or opinions expressed in this research report; 3) Neither I nor any of my family members is an official, director, or member of the advisory board of these companies. None of the Research Analysts or the Research Analyst family has a financial interest in Aldeyra Therapeutics’ securities (including, without limitation, any option, right, security, future, long or short position).

As of June 30, 2022, neither the Company nor its affiliates beneficially owns 1% or more of any class of Aldeyra Therapeutics’ common stock. Neither the research analyst nor the company knew or had reason to know of any other material conflict of interest at the time this research report was published.

The research analyst primarily responsible for preparing the report does not receive compensation based on any specific investment banking services or transactions, but is compensated based on factors including total revenue and the company’s profitability, a large part of which is derived from investment banking services. The Company or its subsidiaries have received compensation from Aldeyra Therapeutics for their non-investment banking services in the past 12 months.

The company or its subsidiaries did not receive compensation from Aldeyra Therapeutics for investment banking in the twelve months prior to that, but will seek compensation from the companies mentioned in this report for investment banking within three months after the research report is published.

The company is not doing market business in Aldeyra Therapeutics as of the date of this research report.

The securities of the company discussed in this report may not be suitable for investors depending on their specific investment objectives and financial situation. Past performance is not a guarantee of future results. This report is provided for informational purposes only, and does not constitute an offer or a solicitation to buy or sell any securities discussed herein in any jurisdiction where this is prohibited. This research report is not intended to provide tax advice or be used to provide tax advice to anyone. Electronic versions of HC Wainwright & Co., LLC’s research reports are made available to all customers simultaneously.

HC Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and does not take into account the specific investment objectives, financial situation and special needs of any particular person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing the investment strategies discussed or recommended in this research report.

Sales representatives, dealers, and other professionals of HC Wainwright & Co. may provide

HC Wainwright & Co., LLC and its affiliates and their officers, directors and employees, excluding its analysts, will from time to time have long or short positions in the securities or derivatives (including options and warrants) of the included companies referenced in this research report.

The information here is based on sources we believe to be reliable but we do not guarantee it to be accurate nor purport to be a complete statement or summary of the available data about the company, industry, or security discussed in the report. All opinions and estimates contained in this report constitute the judgment of the analyst as of the date of this report and are subject to change without notice.

Securities and other financial instruments discussed in this research report: may lose value; Not insured by the Federal Deposit Insurance Corporation; They are subject to investment risks, including potential loss of the principal amount invested.


Investmacro products link

  • The Uranium Company announces the results of solid drilling in the Timsah River 20 July 2022
  • Experimental results show new drug improves dry eye symptoms 20 July 2022
  • Tectonic Minerals closes C$2.3 million private placement 20 July 2022
  • Biopharma looks to expand new drug label in the future 20 July 2022
  • Canadian company with promising assets in the “Lithium Triangle” 20 July 2022
  • Morey Math Lines 20.07.2022 (USDJPY, USDCAD) 20 July 2022
  • Forex Technical Analysis and Forecast 20.07.2022 20 July 2022
  • UK inflation has reached 9.4% which shows that the Bank of England is shamefully incompetent 20 July 2022
  • Analytical Overview of Major Currency Pairs in 2022.07.20 20 July 2022
  • Investors are turning their attention to earning season 20 July 2022



Source link

Add a Comment

Your email address will not be published.